WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis

View/ Open
Citation
World Health Organization. (2018). WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization. http://www.who.int/iris/handle/10665/260494. License: CC BY-NC-SA 3.0 IGO
Description
xi, 31 p.Gov't Doc #
WHO/CDS/TB/2018.7ISBN
9789241550079Collections
Language
EnglishMetadata
Show full item recordRelated items
Showing items related by title and MeSH subject.
-
The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update
World Health Organization (2016) -
Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis
Tabarsi, P.; Baghaei, P.; Hemmati, N.; Mirsaeidi, M.; Kazempour, M.; Mansouri, D.; Masjedi, M.R. (2009)We compared the effectiveness of 2 treatment regimens for isoniazid-resistant tuberculosis [TB] in 42 patients attending a TB referral centre in the Islamic Republic of Iran. The patients were divided into 2 treatment groups: 26 received the 6-month standard HRZE treatment and 16 received a modified treatment of RZE for 6 months. There were no significant differences in age or sex of the groups. With the standard method of treatment, 21 [80.8%] patients were cured, 4 [15.4%] resulted in treatment failure, and 1 [3.8%] died. In the modified treatment ... -
The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance
World Health Organization (2016)